HARMINE
Major Depression
Medical University of ViennaSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
11 Active assets in the Major Depression cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Risperdal Johns Hopkins University | Phase 4 | BBB |
Zelapar Corium Innovations, Inc. | Phase 4 | BBB |
Amitriptyline e-Therapeutics PLC | Phase 4 | BBB |
MELIPRAMINE Hospital de Clinicas de Porto Alegre | Phase 4 | BBB |
Xingpijieyu Formula Peking University Sixth Hospital | Phase 4 | BB |
View all 44 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →